Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Zydus Lifesciences Ltd.
Swot
Zydus Lifesciences Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Zydus Lifesciences Ltd. has 21 Strengths, 2 Weaknesses, 3 Opportunities and 5 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(21)
Weakness
(2)
Opportunity
(3)
Threats
(5)
Others
(5)
Consistent Highest Return Stocks over Five Years
Mid-range Performer (DVM)
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
PEG lower than Industry PEG
Stocks gaining versus previous close, open price and RSI
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Effectively using its capital to generate profit - RoCE improving in last 2 years
Companies with Low Debt
Increasing Revenue every quarter for the past 2 quarters
Increasing profits every quarter for the past 2 quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
RSI indicating price strength
High Volume, High Gain
Top Gainers
Volume Shockers
Increasing Trend in Non-Core Income
Stocks Underperforming their Industry Price Change in the Quarter
Brokers upgraded recommendation or target price in the past three months
FII / FPI or Institutions increasing their shareholding
MFs increased their shareholding last quarter
Recent Broker Downgrades in Reco or Target Price
Companies with high market cap, lower public shareholding
Broker downgrades in price or recommendation in the past one month
US FDA Warning Letter
Insiders sold stocks
Stocks with improving cash flow, with good durability
Rising Delivery Percentage Compared to Prev Day
Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes
Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
